tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Kato H et al. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation. 1994 Transplant. Proc. pmid:7513481
Sewing KF Pharmacokinetics, dosing principles, and blood level monitoring of FK506. 1994 Transplant. Proc. pmid:7527962
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Petuch BR et al. Microbial transformation of immunosuppressive compounds. III. Glucosylation of immunomycin (FR 900520) and FK 506 by Bacillus subtilis ATCC 55060. 1994 J. Ind. Microbiol. pmid:7513528
Shaeffer MS et al. Interaction between FK506 and erythromycin. 1994 Ann Pharmacother pmid:7513563
Douglas CM et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7528927
Lhoëst G et al. Isolation and identification of a FK-506 C36-C37 dihydrodiol from erythromycin-induced rabbit liver microsomes. 1994 J Pharm Biomed Anal pmid:7516189
Kraus-Friedmann N and Feng L Reduction of ryanodine binding and cytosolic Ca2+ levels in liver by the immunosuppressant FK506. 1994 Biochem. Pharmacol. pmid:7529023
Ohtsuka S et al. Experimental rat pancreas transplant: surgical technique and immunological considerations. 1994 Surg. Today pmid:7516209
Cardenas ME et al. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 1994 EMBO J. pmid:7529175
Hisatomi K et al. Limited effectiveness of FK506 administration for ongoing rejection in heterotopic rat heart transplantation. 1994 Surg. Today pmid:7516210
Burkhalter EL et al. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. 1994 J. Hepatol. pmid:7529272
Kawano K et al. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia. 1994 Eur Surg Res pmid:7516291
Morozumi K and Takeda A [Kidney disorders induced by immunosuppressive agents]. 1994 Nippon Naika Gakkai Zasshi pmid:7529294
Wolter K et al. Interaction between FK 506 and clarithromycin in a renal transplant patient. 1994 Eur. J. Clin. Pharmacol. pmid:7532134
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
Alamartine E et al. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. 1994 Nephrol. Dial. Transplant. pmid:7529381
Konishi M et al. Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. 1994 Thymus pmid:7532330
Krentz AJ et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. 1994 Transplantation pmid:7516590
Shapiro R et al. A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. 1994 Clin Transplant pmid:7532475
Ludwig B et al. Characterization of Mip proteins of Legionella pneumophila. 1994 FEMS Microbiol. Lett. pmid:7516906
Murthy JN et al. Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. 1994 Clin. Biochem. pmid:7532556
Donnelly JG and Soldin SJ Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. 1994 Clin. Biochem. pmid:7532557
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Reyes J et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. 1994 Transplant. Proc. pmid:7518137
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Fujisaki S et al. Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. 1994 Transplant. Proc. pmid:7518140
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Spada M et al. Morphology of acute rejection and observation of lymphoproliferative hyperplastic reaction in FK 506 treated pigs after small bowel transplantation. 1994 Transplant. Proc. pmid:7518142
Dumont FJ et al. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes. 1994 J. Pharmacol. Exp. Ther. pmid:7507994
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518974
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Cakaloglu Y et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. 1994 Hepatology pmid:7519161
Luan S et al. Light-regulated, tissue-specific immunophilins in a higher plant. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7508125
Blazar BR et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. 1994 J. Immunol. pmid:7519216
Laifer SA et al. Pregnancy after cardiac transplantation. 1994 Am J Perinatol pmid:7519426
Yoshikawa N et al. Effect of FK-506 on xenografted human Graves' thyroid tissue is severe combined immunodeficient mice. 1994 Clin. Endocrinol. (Oxf) pmid:7519528
Kao PN et al. Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. 1994 J. Biol. Chem. pmid:7519613
Kitamura Y et al. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. 1994 J. Neuroimmunol. pmid:7509816
Tze WJ et al. Successful islet allotransplantation in diabetic rats immunosuppressed with FK506: a functional and immunological study. 1994 Metab. Clin. Exp. pmid:7510012
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Yamauchi T [Multiple abdominal organ transplantation in swine using FK-506]. 1994 Nihon Geka Gakkai Zasshi pmid:7510015
Jiang H et al. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. 1994 Transplant. Proc. pmid:7520631
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Nozaki S et al. Effect of brequinar sodium on accelerated cardiac allograft rejection in presensitized recipients. 1994 Transplant. Proc. pmid:7520633
Masaoka T Problems of bone marrow transplantation in Japan. 1994 Transplant. Proc. pmid:7520634
Okano K et al. Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. 1994 Transplant. Proc. pmid:7520635
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Kuwano K and Arai S The inhibitory effect of FK506 on cytotoxic T-lymphocyte killing. 1994 Immunol. Lett. pmid:7536706
Tsuchida M et al. Effects of irradiation, glucocorticoid and FK506 on cell-surface antigen expression by rat thymocytes: a three-colour flow cytofluorometric analysis. 1994 Immunology pmid:7530693
Meadows RP et al. A computer-based protocol for semiautomated assignments and 3D structure determination of proteins. 1994 J. Biomol. NMR pmid:7510556
Okamoto S et al. The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. 1994 J. Biol. Chem. pmid:7510691
D'Ambrosio R et al. Multicenter comparison of tacrolimus (FK 506) whole blood concentrations as measured by the Abbott IMX analyzer and enzyme immunoassay with methylene chloride extraction. 1994 Ther Drug Monit pmid:7521979
Metcalfe S et al. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. 1994 Cell. Immunol. pmid:7522130
Nichols RA et al. Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. 1994 J. Biol. Chem. pmid:7522234
Nakagawa H et al. Tacrolimus ointment for atopic dermatitis. 1994 Lancet pmid:7522297
Sharkey J and Butcher SP Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. 1994 Nature pmid:7522303
Calne RY Immunosuppression in liver transplantation. 1994 N. Engl. J. Med. pmid:7523947
Schleuning M et al. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. 1994 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7523957
Perotti BY et al. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. 1994 Pharm. Res. pmid:7524055
FDA approved new drug bulletin: aprotinin injection (trasylol), tacrolimus (prograf). 1994 RN pmid:7524131
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Kinoshita I et al. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. 1994 Muscle Nerve pmid:7526208
Cullen BR and Heitman J Human immunodeficiency virus. Chaperoning a pathogen. 1994 Nature pmid:7526224
Connolly JO et al. Renal arteriopathy associated with FK 506 therapy following liver transplantation. 1994 Nephrol. Dial. Transplant. pmid:7526278
Pham SM et al. Cardiac transplantation at the University of Pittsburgh: 1994 update. 1994 Clin Transpl pmid:7547531
Radanyi C et al. The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7526392
Abu-Elmagd K et al. Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. 1994 Clin Transpl pmid:7547533
Ayres RC et al. Peripheral neurotoxicity with tacrolimus. 1994 Lancet pmid:7511197
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Shapiro R et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. 1994 Clin Transpl pmid:7547544
Bendahan J et al. The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. 1994 Transplantation pmid:7511255
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Chavin KD et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. 1994 Transplantation pmid:7511258
Ishioka M et al. FK506 treatment of noninfectious uveitis. 1994 Am. J. Ophthalmol. pmid:7526689
Yano S et al. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes. 1994 Jpn. J. Cancer Res. pmid:7511575
Carroll PB et al. Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results. 1994 Arch Dermatol pmid:7526802
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin. 1994 Int. Immunol. pmid:7511931
Mayrleitner M et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein: effect of FKBP-12 on single channel activity of the skeletal muscle ryanodine receptor. 1994 Cell Calcium pmid:7511990
Hamajima E et al. Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. 1994 Dig. Dis. Sci. pmid:7512015
Matsumoto T et al. Preventive effect of immunosuppressive agents against indomethacin-induced small intestinal ulcers in rats. 1994 Dig. Dis. Sci. pmid:7512017
Platz KP et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. 1994 Transpl. Int. pmid:11271297
Metcalfe S et al. FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes. 1994 Transpl. Int. pmid:11271304
Moutabarrik A et al. Effect of immunosuppressive agents FK 506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytes. 1994 Transpl. Int. pmid:11271305
Winkler M et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. 1994 Transpl. Int. pmid:11271312
Devlin J et al. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group. 1994 Transpl. Int. pmid:11271328
Otto G et al. Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271338
Wong P et al. FK 506 rescue therapy for intractable liver allograft rejection. 1994 Transpl. Int. pmid:11271339